USFDA gives approval for Bortezomib injectionZYDUSLIFE - 606 Change: 7.85 (1.31 %)
News: Aurobindo Pharma’s subsidiary, Eugia Pharma and Zydus Lifesciences has received final approval from USFDA to manufacture and market Bortezomib for injection, 3.5 mg (USRLD: Velcade of Takeda Pharma). Bortezomib for injection is indicated for the treatment of multiple myeloma and mantle cell lymphoma. The approved product has a market size of ~ US$1172 million (MAT March 2022, IQVIA).
Views: Bortezomib is an onco-injectable with big market size and total nine players in US (including Aurobindo and Zydus). The launch offers a window to ramp up revenues from US, depending on market share gains and offset price erosion in US generics. US contributed 50% to FY21 sales to Aurobindo while company aspires to achieve global sales of US$600-700 million by FY24 from generic injectable. For, Zydus US contributed 43% to the top-line in FY21 and amid single digit price erosion, company has set an aspirational target of US$1 billion revenues from US by FY24.